1. Molecular Diagnostic Solutions for Urologic Cancer
2016 Company Presentation
Dr. Jan Groen, President & CEO
©2016 All rights reserved

2. ©2016 All rights reserved
Forward Looking Statement
This presentation contains forward-looking statements & estimates made by the management of the
Company with respect to the anticipated future performance of MDxHealth & the market in which it
operates. Such statements & estimates are based on various assumptions & assessments of known &
unknown risks, uncertainties & other factors, which were deemed reasonable when made but may or may
not prove to be correct. Actual events are difficult to predict & may depend upon factors that are beyond
the Company's control. Therefore, actual results, the financial condition, performance or achievements of
MDxHealth, or industry results, may turn out to be materially different from any future results, performance
or achievements expressed or implied by such statements & estimates. Given these uncertainties, no
representations are made as to the accuracy or fairness of such forward-looking statements & estimates.
MDxHealth disclaims any obligation to update any such forward-looking statement or estimates to reflect
any change in the Company’s expectations with regard thereto, or any change in events, conditions or
circumstances on which any such statement or estimate is based, except to the extent required by Belgian
law.
Any opinions, estimates or forecasts made by analysts are theirs alone and do not represent opinions,
forecasts or predictions of MDxHealth or its management. Requests for copies of analyst reports should be
directed at the respective analyst & institution.
Analyst Coverage
2

3. ©2016 All rights reserved
OUR MISSION
To improve patient outcomes by delivering molecular
diagnostic solutions for urologic cancers.
3

4. ©2016 All rights reserved
4
:
“MDxHealth has maintained its commitment to
advancing molecular diagnostic tests for urological
cancers, continuing to generate data supporting its
ConfirmMDx® for Prostate Cancer test, and
furthermore, recently launched its urine-based
“liquid-biopsy” test, SelectMDx™ for Prostate Cancer.
Frost & Sullivan believes that these two offerings can
significantly reduce the number of men undergoing
unnecessary invasive biopsy procedures, and
importantly helps avoid the associated pain, risk of
complications, and cost.”
Frost & Sullivan Senior Industry
Analyst, Divyaa Ravishankar,
commented:

5. ©2016 All rights reserved
Company Highlights
MDxHealth
Listed on Euronext
publically traded multinational
healthcare company
- Euronext
- (Ticker: MDXH.BR)
Offices
Headquarters in Irvine, CA
- Herstal, Belgium
- Nijmegen, The Netherlands
Improving diagnosis
of urological cancers with
expanding suite of products
- ConfirmMDx for Prostate
- SelectMDx for Prostate
- AssureMDx for Bladder
Market leader
in molecular diagnostics
with a focus on urology
- 2015 FY sales est.$18M
- 35,000 patients tested
5

6. ©2016 All rights reserved
Global Incidence of
Prostate and Bladder Cancer
218,182
164,180
420,899
158,211
288,235
84,062
167,357
27,272
53,36662,380
27,519
4,08520,71617,705
North America & Europe
Annual Numbers
709,134
New cases of prostate cancer
242,273
New cases of bladder cancer
Annual Numbers
1. GLOBOCAN 2012 (IARC) Population forecasts were extracted from the United Nations,
World Population prospects, the 2012 revision. Numbers are computed using age-specific
rates and corresponding populations for 10 age-groups.
India Australia
New Zealand
China Latin America Asia North America Europe
©2016 All rights reserved
6

7. ©2016 All rights reserved
Products and Timelines
MDxHealth
R&D Validation Clinical Utility Launch
MDxHealth
Partnered
US
US & EU
US & EU
US
US
USMGMT**
*
* **
7

8. ©2016 All rights reserved
MDxHealth Business and Product Strategy
US & EU
• Microtome
• PCR
• NGS
• Biomarkers
• Epigenetic (DNA)
• Genetic (RNA)
• Prostate
• Bladder
• Kidney
• Direct sales force
• Partnerships
• Distributors
Instrumentation
Technology &
Biomarkers
Products
(CE & LDT)
Commercial
Channel
8

9. ©2016 All rights reserved
Product Offering
©2016 All rights reserved
9

10. ©2016 All rights reserved
Prostate Cancer Challenges
Annual Numbers
$10 billion 27,540$4 billion
spent on the diagnosis
and screening of
prostate cancer
spent on the treatment
of prostate cancer
men die annually
from prostate cancer
Projected growth prostate
drug market
$4 billion
$5.7 billion
$8.7
billion
2009 2014 2019
Source: Prostate Cancer Market Snapshot: More Then Provenge, The Pink Sheet, Nov 22, 2010. Elsevier Business Intelligence Publications and Products
10

11. ©2016 All rights reserved
Early Detection is Important
Significant Prostate Cancer
Men will develop prostate cancer
in their lifetime
1 in 6
1 in 4
Men will be diagnosed with a
false-negative biopsy
1. Taneja et al: AUA Optimal Techniques of Prostate Biopsy and Specimen Handling 2013.
2. Shen et al: J. Ultrasound Med. 2008; Jun; 27(6): 895-905
11

12. ©2016 All rights reserved
Prostate Cancer in the United Sates
Abnormal
PSA tests
Biopsy
procedures
Diagnosed
with PCa
Deaths
4.7 million
1.3 million
241,000
27,540
Who needs an
initial biopsy?
1
Who needs a
repeat biopsy?
2
Who needs
intervention?
3
Biomarkers
needed
Annual Numbers
Aubry W et al:. American Health Drug and Benefits 2013.6(1): 15-24
12

13. ©2016 All rights reserved
Who Needs a
Biopsy?
13

14. ©2016 All rights reserved
Improve Patient Selection
for Initial Prostate Biopsy
Non-invasive Liquid Biopsy Assay
 RT qPCR method
 Urine-based test
 3 mRNA genes (HOXC3, DLX1, KLK3)
 LDT under CLIA
 CE marked IVD kit
©2016 All rights reserved
14

15. ©2016 All rights reserved
False Negative
Biopsy Challenge

16. ©2016 All rights reserved
Unmet Clinical Need
Prostate biopsy procedures
~1.3
million
Diagnosed with PCa
~241k
With negative biopsy
~1
million
~25% with a false negative biopsy
Aubry W et al:. American Health Drug and Benefits 2013.6(1): 15-24
Need to Improve Patient Selection for Repeat Biopsy
16

17. ©2016 All rights reserved
Lead Product
ConfirmMDx for Prostate Cancer
An LDT to Aid on the Decision for Repeat Biopsy
• RT MSP DNA Methylation assay
• Three epigenetic biomarkers
(GSTPi, RASSF1 and APC)
• LDT under CLIA
• Uses residual tissue biopsy sample
Tissue Biopsy
©2016 All rights reserved
17

18. ©2016 All rights reserved
CLIA
Global Commercialization
Experienced Commercial Team
MDxHealth Direct & Distributors
Distributors
ISO Lab
Contract discussions with distributors
18

19. ©2016 All rights reserved
Commercialization
US and EU
• Laboratory developed test
• Large national sales force
• Established client base
• Reimbursement experience
• Strong KOL support
• CE marked in-vitro diagnostic kits
• Direct sales
• Distributors
• Reimbursement: gov, private ins, patient
• Launched in Benelux
19

20. ©2016 All rights reserved
MDxhealth Proven Commercial Team
Molecular Diagnostic Specialists
Sales Team:
87
Managed Care - 3
Client Services - 6US Sales Force - 37
Partnerships Sales Force - 37
Sales reps with a proven
track record
Unparalleled client serivces
Focused guideline strategy
Strategically utilizing co-marketing
partnership labs
EU Sales Force - 4
Growing international
sales force

21. ©2016 All rights reserved
Growing Number of Ordering Physicians
2012 2013 2014 2015
2,500+200+ 1000+ ~2000
Cumulative Ordering Urologists Since Launch
21
10,000
Urologist in the US
8,500
Office based urologists

22. ©2016 All rights reserved
2012 2013 2014 2015P
>15,000
12,300
7,000
1,100
Guidance
Annual Sales Volume
MDxHealth Lead Product
• Product launched in June 2012
• >35,000 patients tested
22

23. ©2016 All rights reserved
MDxHealth News Flow
2016
 Publication of SelectMDx validation study
 Launch SelectMDx on US market in H1
 Expansion contracts US payors
 Publication of bladder cancer validation study
 Launch AssureMDx in Q4
23